Holding(s) in Company

 | Source: Novo Nordisk A/S Novo Nordisk A/S

In accordance with Section 29 of the Securities Trading Act, Novo Nordisk on 24 October 2007 reported that Capital Group Companies on 12 October 2007 informed Novo Nordisk that Capital Group Companies held 48,127,241 B shares of DKK 2 equal to 14.88% of the total share capital in Novo Nordisk.
 
On 5 December 2007, Novo Nordisk reported that Capital Group Companies on 4 December 2007 informed Novo Nordisk that Capital Group Companies held 93,507,562 B shares of DKK 1 equal to 15.76% of the total share capital in Novo Nordisk. On 10 December 2007, Capital Group Companies informed Novo Nordisk that the reportable threshold has not been crossed because the 93,507,562 B shares of DKK 1 correspond to 14.45% and not 15.76% of the total share capital.
 
Consequently, Novo Nordisk hereby corrects the notification issued 5 December 2007.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
Further information:

 
Stock Exchange Announcement no 36 / 2007
GlobeNewswire

Recommended Reading